Work within the COVID-19 pandemic — the experience of the biobank of the National Medical Research Center of Oncology

Aim. To present the main results and changes in the work of the biobank of the National Medical Research Center of Oncology during the pandemic of coronavirus disease 2019 (COVID-19).

Material and methods. The paper presents a dynamic analysis of the delivery of fresh frozen biological samples from operated patients for three quarters of 2019 and 2020, as well as considers possible ways to implement research projects to collect and deposit materials for the biobank within the COVID-19 pandemic. The work included persons over 18 years old, with primary gastrointestinal cancers, who, upon hospitalization, gave informed consent to transfer biological material to

the biobank. One of the inclusion criteria was the presence of a negative nasopharyngeal swabs tested for SARS-CoV-2 by the polymerase chain reaction. Data calculation and comparative analysis of the results was carried out using the Microsoft Office Excel software package.

Results. It was revealed that in the first quarter of 2019, 34% of biological samples were received from the total amount for the year, while in 2020 — 50%; in the second quarter of 2019 — 35%. The second quarter of 2020 was characterized by change in the schedule of work of institutions due to the COVID-19 pandemic, which led to a 56% decrease in the number of samples compared to the same period in 2019 and amounted to 14% of material collected for the three quarters of2020. In the third quarter of 2020, the flow was restored and amounted to 65 patients, which corresponds to 36% of material collected in this year and is more than in 2019 by 23%.

Conclusion. a critical decrease in the deposited material in the second quarter of 2020 indicated the need to adapt the current biobanking rules inRussia in general and the studied biobank in particular. Possible adaptation ways may consist in the creation of joint projects between groups of scientists from different organizations, taking into account the requirements of information and biological safety. This problem and ways to solve it were widely discussed at international and Russian platforms, including the 4th meeting of the National Association of Biobanks and Biobanking Specialists, dedicated to the organization of biobanking during the COVID-19 pandemic.

1. WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. World Health Organization, Geneva. https://www. who. int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. (11 Feb 2020)

2. Deshmukh V, Tripathi SC, Pandey A et al. COVID-19: a conundrum to decipher. Eur Rev Med Pharmacol Sci. 2020;24(10):5830-41. doi: 10.26355/eurrev_202005_21378

3. Yi Y, Lagniton PhNP, Ye S et al. COVID-19: what has been learned and to be learned about the novel coronavirus disease. International journal of biological sciences. 2020;16(10):1753-66. doi: 10.7150/ijbs.45134

4. Joob B, Wiwanitkit V. Letter to the editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. Journal of Preventive Medicine and Public Health. 2020;53(2):70. doi: 10.3961/jpmph.20.065

5. Khanji MY, Chahal AA, Aung N et al. COVID-19 and the UK biobank-opportunities and challenges for research and collaboration with other large population studies. Front. Cardiovasc. Med. 2020;7:156. doi.org/10.3389/fcvm.2020.00156

6. Stergachis AB, Weiss ST, Green RC. Biobanks could identify medically actionable findings relevant for COVID-19 clinical care. Nature Medicine. 2020;26(70):991. https://doi.org/10.1038/s41591-020-0953-x

7. Henderson MK, Kozlakidis Z, Fachiroh J et al. The Responses of Biobanks to COVID-19. Biopreservation and Biobanking. https://doi.org/10.1089/bio.2020.29074.mkh (31 Aug 2020)